In an experimental gene therapy approach, delivery of MC encoding a TP53 transposon by PSCA-specific hybrid polyplexes into p53-deficient HCT116p53−/−/PSCA colon cancer cells and PTEN-deficient H4PSCA glioma cells led to decreased clonogenic survival. This evidence concerns the gene TP53 and malignant colon neoplasm.